Selvita S.A. Overview
Pro stress-test →Selvita is a leading European CRO supporting pharma and biotech companies with flexible, science-driven R&D services offering integrated or standalone solutions in drug discovery, preclinical studies, and GLP-compliant analytical development. The company helps accelerate new therapies by delivering high-quality data that enables smart decisions and faster time to market.
Strategic Profile
Pro stress-test →Selvita develops dynamically, combining organic growth with acquisitions to deliver research solutions to partners globally. The drug development segment has grown to represent approximately 25% of revenue with 200 employees following the Pozlab acquisition, expanded services including therapeutic antibody discovery and development.
Competitive Landscape
Pro stress-test →Selvita is one of the leading preclinical contract research organizations in Europe. Key competitors in the European CRO/CDMO space include Evotec, Eurofins Discovery, and Sygnature Discovery, with Selvita differentiating through integrated small molecule and biologic drug discovery services, growing CDMO capabilities via PozLab acquisition, and strategic focus on early-to-late stage development across therapeutic areas.
Industry Context
Selvita S.A. operates in Pharmaceutical Contract Research Organization (CRO) / Contract Development and Manufacturing Organization (CDMO).
Key facts
Founded: 2007 · Headquarters: Krakow, Poland · Employees: 950-1000 · Revenue: $95.5M · Market cap: $192M